Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct;51(12):3789-3798.
doi: 10.1007/s00259-024-06789-5. Epub 2024 Jun 11.

Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study

Affiliations
Clinical Trial

Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study

Leonardo Quarta et al. Eur J Nucl Med Mol Imaging. 2024 Oct.

Abstract

Introduction: Prostate-specific membrane antigen radioguided surgery (PSMA-RGS) might identify lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing extended pelvic lymph node dissection (ePLND). The optimal target-to-background (TtB) ratio to define RGS positivity is still unknown.

Materials & methods: Ad interim analyses which focused on 30 patients with available pathological information were conducted. All patients underwent preoperative PSMA positron emission tomography (PET). 99m-Technetium-PSMA imaging and surgery ([99mTc]Tc-PSMA-I&S) was administered the day before surgery. In vivo measurements were conducted using an intraoperative gamma probe. Performance characteristics and implications associated with different TtB ratios were assessed.

Results: Overall, 9 (30%) patients had LNI, with 22 (13%) and 80 (11%) positive regions and lymph nodes, respectively. PSMA-RGS showed uptakes in 12 (40%) vs. 7 (23%) vs. 6 (20%) patients for a TtB ratio ≥ 2 vs. ≥ 3 vs. ≥ 4. At a per-region level, sensitivity, specificity and accuracy for a TtB ratio ≥ 2 vs. ≥ 3 vs. ≥ 4 were 72%, 88% and 87% vs. 54%, 98% and 92% vs. 36%, 99% and 91%. Performing ePLND only in patients with suspicious spots at PSMA PET (n = 7) would have spared 77% ePLNDs at the cost of missing 13% (n = 3) pN1 patients. A TtB ratio ≥ 2 at RGS identified 8 (24%) suspicious areas not detected by PSMA PET, of these 5 (63%) harbored LNI, with one pN1 patient (11%) that would have been missed by PSMA PET. Adoption of a TtB ratio ≥ 2 vs. ≥ 3 vs. ≥ 4, would have allowed to spare 18 (60%) vs. 23 (77%) vs. 24 (80%) ePLNDs missing 2 (11%) vs. 3 (13%) vs. 4 (17%) pN1 patients.

Conclusions: PSMA-RGS using a TtB ratio ≥ 2 to identify suspicious nodes, could allow to spare > 50% ePLNDs and would identify additional pN1 patients compared to PSMA PET and higher TtB ratios.

Keywords: Lymph node dissection; Lymph node metastases; Prostate cancer; Prostate-specific membrane antigen; Radioguided surgery; Staging.

PubMed Disclaimer

Conflict of interest statement

Financial interests: Alberto Briganti and Arturo Chiti declared their conflict of interest.

Alberto Briganti declared the following conflict of interest:

• Astellas Pharma Janseen-Cilag

• OPKO Health

• MDx Health

• Bayer

• miR Scientific

• LLC (“miR”)

• A3P biomedical

• MSD/Astrazeneca

• Ferring

• Pfizer

• Sandoz-Novartis

• Telix Pharmaceuticals

• European Urology, Editor in Chief

Arturo Chiti declared the following conflict of interest:

• Novartis, advisory board; speaker honorarium

• AAA, advisory board; speaker honorarium

• Sirtex, speaker honorarium

• General Electric Healthcare, speaker’s honorarium

• Telix, advisory board

• Bracco, speaker honorarium

• European Journal of Nuclear Medicine and Molecular Imaging, Editor in Chief

Figures

Fig. 1
Fig. 1
[68Ga]Ga-PSMA-11 PET/MRI scan identified a suspicious lymph node at the level of the left obturatory region, as shown in PET (a), MRI (b) and PET/MRI (c) axial view
Fig. 2
Fig. 2
[99mTc]Tc-PSMA-I&S SPECT/CT scan identified a suspicious lymph node at the level of the left obturatory region, as shown in SPECT (a), CT (b) and SPECT/CT (c) axial view
Fig. 3
Fig. 3
Real-time intraoperative use of the Drop-In gamma probe (Crystal Drop-In Probe; Crystal Photonics, Berlin, Germany) for in vivo measurements at the level of the right external iliac region during PSMA-RGS
Fig. 4
Fig. 4
Distribution of maximum diameter of nodal metastasis stratified according to PSMA-RGS positivity based on TtB ratio ≥ 2

References

    1. Maurer T, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68(3). 10.1016/j.eururo.2015.04.034. - PubMed
    1. Barletta F, et al. The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting. Curr Opin Urol. 2023;33(6):502–9. 10.1097/MOU.0000000000001118. (Lippincott Williams and Wilkins). - PubMed
    1. Gandaglia G, et al. Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: results of a planned interim analysis of a prospective phase 2 study. Eur Urol. 2022;82(4):411–8. 10.1016/j.eururo.2022.06.002. - PubMed
    1. Gondoputro W, et al. Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer. J Nucl Med. 2022. 10.2967/jnumed.121.263743. - PMC - PubMed
    1. Maurer T, et al. 99m Technetium-based prostate-specific membrane antigen–radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;75(4):659–66. 10.1016/j.eururo.2018.03.013. - PubMed

Publication types

LinkOut - more resources